NASDAQ:IDXX IDEXX Laboratories - IDXX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $485.53 +3.12 (+0.65%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$462.60▼$497.8550-Day Range$399.93▼$504.2252-Week Range$317.06▼$560.92Volume991,095 shsAverage Volume575,232 shsMarket Capitalization$40.21 billionP/E Ratio61.69Dividend YieldN/APrice Target$485.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability IDEXX Laboratories MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside0.1% Downside$485.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.58Based on 26 Articles This WeekInsider TradingSelling Shares$12.54 M Sold Last QuarterProj. Earnings Growth19.75%From $7.90 to $9.46 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector528th out of 1,027 stocksDiagnostic Substances Industry9th out of 15 stocks 1.4 Analyst's Opinion Consensus RatingIDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $485.00, IDEXX Laboratories has a forecasted downside of 0.1% from its current price of $485.53.Amount of Analyst CoverageIDEXX Laboratories has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IDXX. Previous Next 0.0 Dividend Strength Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. Previous Next 2.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEXX Laboratories has received a 20.02% net impact score from Upright. Idexx Laboratories seems to create the most significant positive value in categories "Taxes", "Nutrition", and "Jobs". The positive contribution in the "Nutrition" impact category is mostly driven by its "Veterinary x-rays", "Veterinary hematology analyzers", and "Veterinary services for livestock" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEXX Laboratories is -2.80. Previous Next 3.1 News and Social Media Coverage News SentimentIDEXX Laboratories has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.Search Interest20 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,541,681.00 in company stock.Percentage Held by InsidersOnly 2.06% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions87.90% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 19.75% in the coming year, from $7.90 to $9.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 61.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.56.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 61.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 141.66.Price to Earnings Growth RatioIDEXX Laboratories has a PEG Ratio of 2.94. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 59.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IDEXX Laboratories (NASDAQ:IDXX) StockIDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in WestRead More Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXX Stock News HeadlinesFebruary 7, 2023 | americanbankingnews.comResearch Analysts Set Expectations for IDEXX Laboratories, Inc.'s FY2023 Earnings (NASDAQ:IDXX)February 6, 2023 | finance.yahoo.comAnalyst Says IDEXX Laboratories' Long-Term Growth Outlook Remains StrongFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...February 6, 2023 | msn.comIDEXX Laboratories Posts Better-Than-Expected Fourth-Quarter Results, Offers In-Line Full-Year 2023 GuidanceFebruary 6, 2023 | finanznachrichten.deIDEXX Laboratories, Inc.: IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 ResultsFebruary 6, 2023 | baystreet.caIDEXX Stumbles on Q4 and Full-Year FiguresFebruary 6, 2023 | markets.businessinsider.comIDEXX Laboratories Sees Higher Earnings, Revenues In FY23 - UpdateFebruary 6, 2023 | markets.businessinsider.comIDEXX Laboratories Inc Q4 Income Climbs, Beats estimatesFebruary 7, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.February 6, 2023 | finance.yahoo.comIDEXX Laboratories Announces Fourth Quarter and Full Year 2022 ResultsFebruary 6, 2023 | finance.yahoo.comIdexx Laboratories (IDXX) Q4 Earnings and Revenues Beat EstimatesFebruary 6, 2023 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Updates FY23 Earnings GuidanceFebruary 5, 2023 | reuters.comIDXX.OQ - | Stock Price & Latest News | ReutersFebruary 4, 2023 | finance.yahoo.comIs It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?February 4, 2023 | americanbankingnews.comIDEXX Laboratories (IDXX) Set to Announce Quarterly Earnings on MondayFebruary 3, 2023 | msn.comA Preview Of IDEXX Laboratories's EarningsFebruary 3, 2023 | seekingalpha.comIDEXX Laboratories Q4 2022 Earnings PreviewJanuary 31, 2023 | marketwatch.comIDEXX Laboratories Inc. stock falls Tuesday, underperforms marketJanuary 31, 2023 | finance.yahoo.comSONVY or IDXX: Which Is the Better Value Stock Right Now?January 29, 2023 | americanbankingnews.comIDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $473.13 Average PT from AnalystsJanuary 29, 2023 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $530.00 at The Goldman Sachs GroupJanuary 26, 2023 | finance.yahoo.comIDEXX Laboratories to Release 2022 Fourth Quarter and Full Year Financial ResultsJanuary 25, 2023 | finance.yahoo.comIdexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseJanuary 25, 2023 | finance.yahoo.comIDEXX Laboratories Is Barking Up the Right TreeJanuary 24, 2023 | marketwatch.comIDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitorsJanuary 18, 2023 | finance.yahoo.comHere's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade AgoJanuary 12, 2023 | finance.yahoo.comDoes IDEXX Laboratories (NASDAQ:IDXX) Have A Healthy Balance Sheet?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXX Company Calendar Last Earnings2/06/2023Today2/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:IDXX CUSIP45168D10 CIK874716 Webwww.idexx.com Phone(207) 556-0300Fax207-556-4346Employees10,350Year Founded1983Price Target and Rating Average Stock Price Forecast$485.00 High Stock Price Forecast$582.00 Low Stock Price Forecast$415.00 Forecasted Upside/Downside-0.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$7.87 Trailing P/E Ratio61.69 Forward P/E Ratio61.46 P/E Growth2.94Net Income$744.84 million Net Margins20.05% Pretax Margin25.11% Return on Equity118.38% Return on Assets26.06% Debt Debt-to-Equity Ratio1.60 Current Ratio0.89 Quick Ratio0.59 Sales & Book Value Annual Sales$3.22 billion Price / Sales12.51 Cash Flow$10.08 per share Price / Cash Flow48.16 Book Value$8.14 per share Price / Book59.65Miscellaneous Outstanding Shares82,820,000Free Float81,111,000Market Cap$40.21 billion OptionableOptionable Beta1.17 Social Links Key ExecutivesJonathan J. MazelskyPresident, Chief Executive Officer & DirectorBrian Patrick McKeonChief Financial Officer, Treasurer & Executive VPKen GradyChief Information Officer & Senior VPMurthy YerramilliSenior Vice President-Research & DevelopmentMartin Alexander SmithChief Technology Officer & Executive VPKey CompetitorsDexComNASDAQ:DXCMBiogenNASDAQ:BIIBCenteneNYSE:CNCAlconNYSE:ALCHaleonNYSE:HLNView All CompetitorsInsiders & InstitutionsKentucky Retirement SystemsBought 29 shares on 2/6/2023Ownership: 0.008%Parallel Advisors LLCBought 68 shares on 2/6/2023Ownership: 0.003%Arete Wealth Advisors LLCSold 46 shares on 2/6/2023Ownership: 0.002%Brinker Capital Investments LLCSold 41 shares on 2/6/2023Ownership: 0.001%Glassman Wealth ServicesSold 42 shares on 2/6/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions IDXX Stock - Frequently Asked Questions Should I buy or sell IDEXX Laboratories stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDXX shares. View IDXX analyst ratings or view top-rated stocks. What is IDEXX Laboratories' stock price forecast for 2023? 8 analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they predict the company's share price to reach $485.00 in the next year. This suggests that the stock has a possible downside of 0.1%. View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts. How have IDXX shares performed in 2023? IDEXX Laboratories' stock was trading at $407.96 on January 1st, 2023. Since then, IDXX shares have increased by 19.0% and is now trading at $485.53. View the best growth stocks for 2023 here. When is IDEXX Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023. View our IDXX earnings forecast. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Monday, February, 6th. The company reported $2.05 EPS for the quarter, topping analysts' consensus estimates of $1.92 by $0.13. The firm earned $828.60 million during the quarter, compared to analyst estimates of $820.91 million. IDEXX Laboratories had a net margin of 20.05% and a trailing twelve-month return on equity of 118.38%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.89 EPS. What guidance has IDEXX Laboratories issued on next quarter's earnings? IDEXX Laboratories updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share guidance of $9.27-$9.75 for the period, compared to the consensus EPS estimate of $9.50. The company issued revenue guidance of $3.59 billion-$3.69 billion, compared to the consensus revenue estimate of $3.62 billion. What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO? 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees. What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP). What is IDEXX Laboratories' stock symbol? IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX." Who are IDEXX Laboratories' major shareholders? IDEXX Laboratories' stock is owned by many different retail and institutional investors. Top institutional investors include LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Manning & Napier Group LLC (0.21%), Welch & Forbes LLC (0.21%) and Bank Julius Baer & Co. Ltd Zurich (0.20%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek. View institutional ownership trends. How do I buy shares of IDEXX Laboratories? Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IDEXX Laboratories' stock price today? One share of IDXX stock can currently be purchased for approximately $485.53. How much money does IDEXX Laboratories make? IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $40.21 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.87 on an earnings per share basis. How many employees does IDEXX Laboratories have? The company employs 10,350 workers across the globe. How can I contact IDEXX Laboratories? IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346. This page (NASDAQ:IDXX) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.